Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Neil L. Spector(Tennessee Oncology), Sarah Bacus(Tennessee Oncology)

Journal of Clinical Oncology

February 1, 2005

10.1200/jco.2005.12.157

Cited by 364

Related Papers

The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins

|British Journal of Cancer|2004|86

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor

|PLoS ONE|2015|31